Sanofi

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Regeneron plots DTC advertising and discount push to put Eylea back on track
Regeneron plots DTC advertising and discount push to put Eylea back on track
Fierce Pharma
Regeneron
Sanofi
Eylea
DTC advertising
Flag link:
Sanofi has been stockpiling drugs for no-deal Brexit: WSJ
Sanofi has been stockpiling drugs for no-deal Brexit: WSJ
Yahoo/Reuters
Sanofi
drug shortages
Brexit
Europe
Great Britain
Flag link:
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
Yahoo/Zacks.com
Sanofi
earnings
Flag link:
Sanofi Ventures leads $17m round for Click Therapeutics
Sanofi Ventures leads $17m round for Click Therapeutics
Drug Delivery Business News
Click Therapeutics
Sanofi
digital therapeutics
smoking cessation
Clickotine
Flag link:
Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program
Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program
Endpoints
Sanofi
Revolution Medicines
cancer
Flag link:
Sanofi to shut down immediately Mourenx factory over excessive toxic waste
Sanofi to shut down immediately Mourenx factory over excessive toxic waste
GoinPharma
Sanofi
France
pollution
drug manufacturing
Flag link:
French pharma Sanofi names new head of research and CFO, big changes to come
French pharma Sanofi names new head of research and CFO, big changes to come
GoinPharma
Sanofi
Flag link:
More than $100 Billion Spent on M&A in the First 6 Months of 2018
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
Flag link:
Sanofi’s Andre Turenne Is Slated to Become Voyager Therapeutics CEO
Sanofi’s Andre Turenne Is Slated to Become Voyager Therapeutics CEO
Xconomy
Voyager Therapeutics
Andre Turenne
Sanofi
Pharma CEOs
Flag link:
Celgene pledges to limit price hikes—or does it?
Celgene pledges to limit price hikes—or does it?
Fierce Pharma
Allergan
Sanofi
Celgene
drug pricing
Flag link:
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
Endpoints
Regeneron
Sanofi
Dupixent
drug pricing
Flag link:
Sanofi gets serious in China with plans to hire 300 for $76M R&D site in Chengdu
Sanofi gets serious in China with plans to hire 300 for $76M R&D site in Chengdu
Endpoints
China
Sanofi
clinical trials
R&D
Flag link:
Sanofi, Advent finally shake hands on $2.2B European generics sale
Sanofi, Advent finally shake hands on $2.2B European generics sale
Fierce Pharma
Sanofi
Europe
generics
Advent International
Zentiva
M&A
Flag link:
Sensile, Sanofi, and Verily Form Diabetes Dream Team
Sensile, Sanofi, and Verily Form Diabetes Dream Team
Medical Devices and Diagnostics Industry
diabetes
Verily
Sensile Medical
Sanofi
devices
insulin patch pump
Flag link:
Sanofi's Dupixent scores NICE recommendation after price cut
Sanofi's Dupixent scores NICE recommendation after price cut
Fierce Pharma
Sanofi
NICE
atopic dermatitis
Dupixent
Flag link:
Latecomer Sanofi looks to catch next wave of cancer therapies
Latecomer Sanofi looks to catch next wave of cancer therapies
Reuters
Sanofi
cancer
immuno-oncology
oncology
Flag link:
Evotec seals deal for Sanofi’s infectious disease unit
Evotec seals deal for Sanofi’s infectious disease unit
Fierce Biotech
Evotec
Sanofi
M&A
infectious diseases
Flag link:
Study confirms higher risk of dengue in kids who got Sanofi vaccine
Study confirms higher risk of dengue in kids who got Sanofi vaccine
Reuters
Sanofi
dengue
vaccines
Flag link:
Can Sanofi compete in lung cancer? With I-O med cemiplumab, it’s aiming for third
Can Sanofi compete in lung cancer? With I-O med cemiplumab, it’s aiming for third
Fierce Pharma
Sanofi
PD-1 inhibitors
cemiplumab
lung cancer
Flag link:

Pages